Hansoh Pharmaceutical's Aumolertinib Selected for Two Poster Presentations at ASCO 2022 Highlighting Efficacy in Brain Metastases and Combination Therapy

The 2022 American Society of Clinical Oncology (ASCO) Annual Meeting is about to be held online and in Chicago, USA. According to Hansoh Pharma, the latest research progress on its Class 1 innovative drug, Aumolertinib Mesylate Tablets, will be released during the conference.

Two weeks ago, JCO, the official journal of ASCO, authoritatively released part of the data from the AENEAS study led by Professor Lu Shun from Shanghai Chest Hospital, Shanghai Jiao Tong University. The AENEAS study is a registrational trial comparing Aumolertinib (Ameitinib) with Gefitinib as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations, with over 400 participants in total. At the 2021 ASCO Annual Meeting, this study made its debut, showing a median progression-free survival (mPFS) of 19.3 months, marking the first time that PFS data of an EGFR-TKI monotherapy in the first-line setting exceeded 19 months. This year’s ASCO Annual Meeting will further release the latest findings on its brain metastasis subgroup, with the poster titled “Efficacy and Safety of Aumolertinib as First-Line Treatment for Brain Metastases in EGFR-Mutated NSCLC: AENEAS Study,” Abstract Code: 9096.

Currently, the third-generation EGFR-TKI is the first-line standard treatment for EGFR mutation-positive advanced NSCLC. However, the efficacy of single-agent therapy seems to have reached a bottleneck. The combination of anti-angiogenic drugs + TKI is a new strategy to further improve efficacy and extend patient survival. This year's ASCO Annual Meeting will feature the first release of the ATTENTION study protocol led by Professor Hu Yi from the 301 Hospital as the leading PI. This is a multicenter, randomized, open-label, controlled Phase III clinical trial. The poster abstract is titled "Efficacy and Safety of Aumolertinib in Combination with Apatinib versus Aumolertinib Monotherapy as First-Line Treatment for Advanced NSCLC with EGFR-Sensitizing Mutations," Abstract Code: TPS9151 (371056).

Currently, research on Aumetinib in combination with chemotherapy, anti-angiogenic therapy, adjuvant treatment, and neoadjuvant treatment is ongoing.